Hot Products
| Catalog No. | Information |
| CFN99731 | Glabridin Glabridin is a GABAA receptor positive modulator promoting fatty acid oxidation and improving learning and memory, which has antioxidative,anti-inflammatory, antimalarial, estrogen receptor agonism, anti-metastasis, anti-melanogenesis and neuroprotective effects. Glabridin may possess a therapeutic effect on metabolic disorders( such as diabetes and hyperglycemia), by modulating glucose metabolism through AMPK in skeletal muscle cells. |
| CFN93042 | Glabrol Glabrol is a PTP1B inhibitor, it is also a CYP1B1 inhibitor, it shows inhibition of CYP1B1 in live cell assay with the IC50 value of 15 uM. Glabrol has hypnotic effects, it induces sleep via a positive allosteric modulation of GABA(A)-BZD receptors. Glabrol possesses significant antimicrobial activity in vitro. Glabrol may have potential therapy for the treatment in obesity and type 2 diabetes patients, it shows a noncompetitive type of inhibition against diacylglycerol acyltransferase (DGAT) with an IC50 value of 8.0 microM. |
| CFN93135 | Glabrolide Reference standards. |
| CFN93041 | Glabrone Glabrone shows antiviral activity against influenza virus. It also exhibits significant PPAR-gamma ligand-binding activity. |
| CFN99256 | Glaucin B Glaucin B is a new bitter limonoid. |
| CFN90408 | Glaucine Glaucine has antitussive, antioxidative potential and antiviral activities, it may be an anti-arthritic agent, it can enhance LPS and zymosan-induced IL-10 production. Glaucine can inhibit the migration and invasion of human breast cancer cells by MMP-9 inhibitory activity, attenuating IκBα and NF-κB activities. |
| CFN90207 | Glaucocalyxin A Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand. Glaucocalyxin A has regulation of microglia activity, can attenuate lipopolysaccharide -stimulated neuroinflammation through NF-κB and p38 MAPK signaling pathways.Glaucocalyxin A may become a potential anti-fibrotic agent in Idiopathic pulmonary fibrosis (IPF) management, it can effectively ameliorate pulmonary fibrosis through the antagonism of leukocyte infiltration and proinflammatory cytokine production. |
| CFN95299 | Glaucoside A Anticancer. Glaucoside A was evaluated against the HT-29 and HCT 116 human colon cancer cell lines. |
| CFN95300 | Glaucoside C Anticancer. Glaucoside C was evaluated against the HT-29 and HCT 116 human colon cancer cell lines. |
| CFN97977 | Glepidotin B Reference standards. |
